Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Custom Services International.

This article was originally published in The Gray Sheet

Executive Summary

Petitions FDA to revise its Sept. 30 final rule on natural rubber latex containing devices. The firm requests that the agency eliminate the requirement that condom manufacturers must print the statement: "Caution: This Product Contains Natural Rubber Latex Which May Cause Allergic Reactions" on individually wrapped condoms. Echoing concerns initially expressed by the Health Industry Manufacturers Association in October 1996, the petition notes that the additional statement "cannot be placed on the principal display panel...without regulatory relief as to some other required statement, or a waiver for further decrease in the type size" ("The Gray Sheet" Oct. 6, p. 3). The firm believes the existing warnings printed on the packaging are sufficient...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel